Renal cancer vaccine - NewLink GeneticsAlternative Names: HyperAcute™ Renal; Renal immunotherapy - NewLink Genetics
Latest Information Update: 17 Mar 2014
At a glance
- Originator NewLink Genetics Corporation
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase I Renal cancer
Most Recent Events
- 01 Dec 2013 Preclinical trials in metastatic Renal cancer in USA (Intradermal)